Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The efforts to develop electron lens systems that can achieve atomic resolution in transmission electron microscopy have been awarded the most prestigious accolade dedicated to nanoscience.
As the spread of SARS-CoV-2 has triggered worldwide closures of research labs and facilities, Kostas Kostarelos shares his views on what may be going wrong in the fight against COVID-19 and how the nanoscience community could and should contribute.
The identification and isolation of individuals with COVID-19 can help to flatten the epidemic curve and win us time to wait for the vaccine development and production, and antiviral drug therapies.
Although we seem to understand how nanoscience can impact the environment, we seem to be far off using nanotechnology for environmental remediation, says Chris Toumey.
Chloroquine — an approved malaria drug — is known in nanomedicine research for the investigation of nanoparticle uptake in cells, and may have potential for the treatment of COVID-19.
The addition of carbon nanotubes to the SIN (‘Substitute It Now’) list has evoked reactions from nanomedicine and nanotoxicology researchers, who ask for a fairer and more recent research-based risk assessment of carbon nanotubes.
Nature Nanotechnology will work with authors and reviewers to establish the best practises to make data available and usable by a wide scientific community.
Results from new artificial water channels for desalination show the importance of exploring alternative solutions to simply optimizing existing technologies.
Chris Toumey explores the way in which reactions to nanotechnology from different religious denominations can be translated to other emerging technologies.
The cancer nanomedicine field is heading in two directions — debating whether the clinical translation of nanomaterials should be accelerated or whether some of the long-standing drug delivery paradigms have to be challenged first.
The regulatory approval of Onpattro, a lipid nanoparticle-based short interfering RNA drug for the treatment of polyneuropathies induced by hereditary transthyretin amyloidosis, paves the way for clinical development of many nucleic acid-based therapies enabled by nanoparticle delivery.